New drug cocktail targets tough cancers with KRAS G12D mutation
NCT ID NCT06385678
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This study tests a new drug called HRS-4642 combined with other cancer medicines in people with advanced solid tumors that have a specific genetic change (KRAS G12D). The goal is to check safety, find the best dose, and see if the combination shrinks tumors. About 47 adults aged 18-75 with tumors that cannot be removed or have spread are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED KRAS G12D MUTANT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai East Hospital
Shanghai, Shanghai Municipality, 200120, China
Conditions
Explore the condition pages connected to this study.